Health
Leqembi® approved for IV maintenance treatment in China
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National Medical Products Administration (NMPA) in China.
About this update from Bioarctic Ab Class B
[{"type":"text","content":"STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National Medical Products Administration (NMPA) in China.","length":345,"tagName":"p"},{"type":"text","content":"In January 2024, lecanemab was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.","length":480,"tagName":"p"},{"type":"text","content":"AD is a progressive, relentless disease characterized by formation of protein deposits known as plaques made of amyloid-beta aggregates and neurofibrillary tangles made of tau protein in the brains of people living with AD. It is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after plaque removal.[i],[ii],[iii],[iv] The data show that Aβ protofibrils[1] and tau tangles play roles in the neurodegeneration process,i,ii and Leqembi is the only approved therapy that fights AD in two ways – targeting both amyloid plaque and protofibrils, which can impact tau downstream.","length":638,"tagName":"p"},{"type":"text","content":"Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.","length":569,"tagName":"p"},{"type":"text","content":"This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Re...